AbbVie Focuses On Humira’s Formulary Positioning Ahead Of US Biosimilars

 
• By Joseph Haas

A year out from US competition to top-seller Humira, AbbVie is negotiating for formulary position alongside biosimilars. Analysts said success there could delay some patent cliff pain for the originator until 2024.

AbbVie exterior
AbbVie talked about US formulary positioning for Humira post-patent expiry • Source: Alamy

More from Strategy

More from Business